RS51215B - Novi derivati 3-fenilpropionske kiseline i njihova upotreba kao ppar gama receptora liganda - Google Patents

Novi derivati 3-fenilpropionske kiseline i njihova upotreba kao ppar gama receptora liganda

Info

Publication number
RS51215B
RS51215B RSP-2010/0003A RSP20100003A RS51215B RS 51215 B RS51215 B RS 51215B RS P20100003 A RSP20100003 A RS P20100003A RS 51215 B RS51215 B RS 51215B
Authority
RS
Serbia
Prior art keywords
alkyl
ppar
aryl
formula
new
Prior art date
Application number
RSP-2010/0003A
Other languages
English (en)
Inventor
Zbigniew Majka
Katarzyna Rusin
Dominik Kludkiewicz
Daniel Sulikowski
Krzysztof Kurowski
Katarzyna Matusiewicz
Tomasz Stawinski
Piotr Kowalczyk
Original Assignee
Adamed Sp. Z.O.O.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamed Sp. Z.O.O. filed Critical Adamed Sp. Z.O.O.
Publication of RS51215B publication Critical patent/RS51215B/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18Oxygen atoms
    • C07D263/20Oxygen atoms attached in position 2
    • C07D263/24Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/36One oxygen atom
    • C07D263/38One oxygen atom attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/42Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RSP-2010/0003A 2005-01-19 2006-01-17 Novi derivati 3-fenilpropionske kiseline i njihova upotreba kao ppar gama receptora liganda RS51215B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL372332A PL372332A1 (pl) 2005-01-19 2005-01-19 Nowe związki, pochodne kwasu 3-fenylopropionowego
PCT/EP2006/050234 WO2006077206A1 (en) 2005-01-19 2006-01-17 New 3-phenylpropionic acid derivatives and their use as ppar- gamma rezeptor liganden

Publications (1)

Publication Number Publication Date
RS51215B true RS51215B (sr) 2010-12-31

Family

ID=36046977

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2010/0003A RS51215B (sr) 2005-01-19 2006-01-17 Novi derivati 3-fenilpropionske kiseline i njihova upotreba kao ppar gama receptora liganda

Country Status (25)

Country Link
US (2) US7309791B2 (sr)
EP (1) EP1874745B1 (sr)
JP (1) JP2008527021A (sr)
KR (1) KR100889447B1 (sr)
CN (1) CN101098862A (sr)
AT (1) ATE448214T1 (sr)
AU (1) AU2006207492B8 (sr)
BR (1) BRPI0606501A2 (sr)
CA (1) CA2590575C (sr)
CY (1) CY1109678T1 (sr)
DE (1) DE602006010353D1 (sr)
DK (1) DK1874745T3 (sr)
ES (1) ES2336358T3 (sr)
HR (1) HRP20090647T1 (sr)
IL (1) IL183564A0 (sr)
MX (1) MX2007008114A (sr)
NO (1) NO20074173L (sr)
PL (2) PL372332A1 (sr)
PT (1) PT1874745E (sr)
RS (1) RS51215B (sr)
RU (1) RU2369602C2 (sr)
SI (1) SI1874745T1 (sr)
UA (1) UA89940C2 (sr)
WO (1) WO2006077206A1 (sr)
ZA (1) ZA200705889B (sr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL371841A1 (pl) * 2004-12-20 2006-06-26 ADAMED Sp.z o.o. Nowe związki pochodne kwasu 3-fenylopropionowego
EP1951692B1 (en) * 2005-11-07 2010-08-18 Irm Llc Oxazole and thiazole ppar modulator
WO2009132310A1 (en) * 2008-04-25 2009-10-29 Wisconsin Alumni Research Foundation Inhibitors of udp-galactopyranose mutase thwart mycobacterial growth
EP2380884B1 (en) * 2008-12-01 2014-02-12 Mitsubishi Tanabe Pharma Corporation Carboxylic acid derivative containing thiazole ring and pharmaceutical use thereof
RS63074B1 (sr) * 2014-07-03 2022-04-29 Celgene Quanticel Research Inc Inhibitori lizin specifične demetilaze-1
US10080757B2 (en) 2016-03-11 2018-09-25 Wisconsin Alumni Research Foundation Inhibitors of UDP-galactopyranose mutase

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1552125A (en) 1975-06-07 1979-09-05 Lilly Industries Ltd 2-acylamino oxazoles
JPS58125039A (ja) 1982-01-21 1983-07-25 Konishiroku Photo Ind Co Ltd 写真用2当量イエロ−カプラ−
US5296486A (en) * 1991-09-24 1994-03-22 Boehringer Ingelheim Pharmaceuticals, Inc. Leukotriene biosynthesis inhibitors
AU3959193A (en) 1992-04-10 1993-11-18 Smithkline Beecham Plc Heterocyclic compounds and their use in the treatment of type II-diabetes
EP0751943A1 (en) 1994-03-12 1997-01-08 Yuhan Corporation Triazole compounds and processes for the preparation thereof
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
KR20010030881A (ko) 1997-10-02 2001-04-16 가와무라 요시부미 아미도카르복실산 유도체
JP4618845B2 (ja) 1999-06-09 2011-01-26 杏林製薬株式会社 ヒトペルオキシゾーム増殖薬活性化受容体(PPAR)αアゴニストとしての置換フェニルプロピオン酸誘導体
ES2215719T3 (es) 1999-09-08 2004-10-16 Glaxo Group Limited Antagonista ppar oxazol.
FR2808798A1 (fr) 2000-05-09 2001-11-16 Hoechst Marion Roussel Inc Nouveaux derives antagonistes du recepteur de la vitronectine
EP1414785A1 (en) 2001-07-30 2004-05-06 Novo Nordisk A/S Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc
JP2005503377A (ja) 2001-07-30 2005-02-03 ノボ ノルディスク アクティーゼルスカブ 新規ビニルn−(2−ベンゾイルフェニル)−l−チロシン誘導体及び抗糖尿病剤等へのそれらの使用
PL371841A1 (pl) * 2004-12-20 2006-06-26 ADAMED Sp.z o.o. Nowe związki pochodne kwasu 3-fenylopropionowego
PL372356A1 (pl) * 2005-01-20 2006-07-24 ADAMED Sp.z o.o. Nowe związki, pochodne kwasu 3-fenylopropionowego

Also Published As

Publication number Publication date
NO20074173L (no) 2007-08-14
IL183564A0 (en) 2007-09-20
WO2006077206A1 (en) 2006-07-27
CY1109678T1 (el) 2014-08-13
CA2590575A1 (en) 2006-07-27
HRP20090647T1 (hr) 2010-01-31
US20070161799A1 (en) 2007-07-12
UA89940C2 (en) 2010-03-10
AU2006207492B2 (en) 2009-03-05
CA2590575C (en) 2010-09-21
EP1874745B1 (en) 2009-11-11
ZA200705889B (en) 2009-03-25
US7629370B2 (en) 2009-12-08
KR20070097112A (ko) 2007-10-02
DE602006010353D1 (de) 2009-12-24
AU2006207492B8 (en) 2009-03-26
EP1874745A1 (en) 2008-01-09
PL372332A1 (pl) 2006-07-24
AU2006207492A1 (en) 2006-07-27
PL1874745T3 (pl) 2010-03-31
RU2007131423A (ru) 2009-02-27
SI1874745T1 (sl) 2010-02-26
DK1874745T3 (da) 2009-12-21
ATE448214T1 (de) 2009-11-15
PT1874745E (pt) 2010-01-13
US7309791B2 (en) 2007-12-18
US20060160868A1 (en) 2006-07-20
MX2007008114A (es) 2007-08-02
JP2008527021A (ja) 2008-07-24
KR100889447B1 (ko) 2009-03-24
CN101098862A (zh) 2008-01-02
ES2336358T3 (es) 2010-04-12
RU2369602C2 (ru) 2009-10-10
BRPI0606501A2 (pt) 2009-06-30

Similar Documents

Publication Publication Date Title
MY142807A (en) Benzimidazole derivative and use thereof.
ZA200705889B (en) New 3-phenylpropionic acid derivatives and their use as PPAR-GAMMA receptor ligands
NO20044731L (no) Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere
MXPA04009784A (es) Tiazolidin-4-carbonitrilos y analogos y su uso como inhibidores de dipeptidil-peptidas.
UA94390C2 (ru) Применение производных индолинонов, предназначенных для лечения или предупреждения идиопатического фиброза легких
WO2004013120A8 (en) Novel benzodioxoles
EA200701745A1 (ru) Циклопропанкарбоксамидные производные
TW200716648A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
MY156747A (en) Isoxazolo-pyridine derivatives
TW200616994A (en) Novel thiophene derivatives
CY1112800T1 (el) Η χρηση υποκαθιστουμενων κυανοπυρρολιδινων για τη θεραπεια της υπερλιπιδαιμιας
NO20072371L (no) Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
MX2009010790A (es) Derivados de heteroarilo biciclico fusionados.
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
TW200635911A (en) Sulfanyl substituted phenyl methanones
UA89807C2 (ru) Производные 3-фенилпропионовой кислоты для лечения диабета
WO2004066952A3 (en) Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases
MXPA06000269A (es) Tiofenilaminoimidazolinas.
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
MXPA05006271A (es) Metodo para el tratamiento de desordenes del movimiento usando derivados de acido barbiturico.
RS20060053A (en) Substituted furochromenes, preparation thereof and their antiinflammatory action
NO20064806L (no) Formamidderivater anvendelige som adenoceptor
NO20064805L (no) Sammensetninger for behandling av sykdommer
MX2008002753A (es) Derivados de piridazinona utilizados para el tratamiento de dolor.
TW200738637A (en) Compounds having activity at NK3 receptor and uses thereof in medicine